{
    "id": 25341,
    "fullName": "BIRC2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BIRC2 positive indicates the presence of the BIRC2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 329,
        "geneSymbol": "BIRC2",
        "terms": [
            "BIRC2",
            "API1",
            "c-IAP1",
            "cIAP1",
            "Hiap-2",
            "HIAP2",
            "MIHB",
            "RNF48"
        ]
    },
    "variant": "positive",
    "createDate": "09/15/2016",
    "updateDate": "09/08/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8439,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0917 treatment induced rapid decrease of Birc2 (cIAP-1) level, and resulted in complete response in 5.5% (2/36) of patients with advanced solid tumors (PMID: 27076626).",
            "molecularProfile": {
                "id": 26248,
                "profileName": "BIRC2 positive"
            },
            "therapy": {
                "id": 3639,
                "therapyName": "GDC-0917",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6658,
                    "pubMedId": 27076626,
                    "title": "A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076626"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8440,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0917 treatment induced rapid decrease of Birc2 (cIAP-1) level, and resulted in sustained complete response in a patient with mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach, who remained disease-free for over 2 years after discontinuing treatment (PMID: 27076626).",
            "molecularProfile": {
                "id": 26248,
                "profileName": "BIRC2 positive"
            },
            "therapy": {
                "id": 3639,
                "therapyName": "GDC-0917",
                "synonyms": null
            },
            "indication": {
                "id": 50909,
                "name": "MALT lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6658,
                    "pubMedId": 27076626,
                    "title": "A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076626"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8363,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, T-3256336 inhibited growth of pancreatic cancer cells only in the presence of exogenous TNF in culture, but induced Birc2 (cIAP-1) degradation and tumor regression in cell line xenograft models, potentially dependent on the circulating murine TNF (PMID: 27608596).",
            "molecularProfile": {
                "id": 26249,
                "profileName": "BIRC2 pos TNF pos"
            },
            "therapy": {
                "id": 4715,
                "therapyName": "T-3256336",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6633,
                    "pubMedId": 27608596,
                    "title": "T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27608596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8441,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GDC-0917 treatment induced rapid decrease of Birc2 (cIAP-1) level, and resulted in complete response in an ovarian cancer patient harboring germline BRCA1 mutation, who remained disease-free for 18 months after discontinuing treatment (PMID: 27076626).",
            "molecularProfile": {
                "id": 26331,
                "profileName": "BIRC2 pos BRCA1 mut"
            },
            "therapy": {
                "id": 3639,
                "therapyName": "GDC-0917",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6658,
                    "pubMedId": 27076626,
                    "title": "A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076626"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9218,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TL32711 (birinapant) combined with radiotherapy, which induced TNF-alpha, led to increased sensitivity in a head and neck squamous cell carcinoma cell line xenograft model positive for BIRC2 and over expressing FADD, demonstrating complete tumor regression (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells positive for BIRC2 and over expressing FADD demonstrated sensitivity to treatment with TL32711 (birinapant) with or without TNF-alpha, resulting in increased cell death and cell-cycle arrest in culture (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9217,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a head and neck squamous cell carcinoma cell line positive for both BIRC2 and FADD demonstrated sensitivity to TL32711 (Birinapant), resulting in increased cell death in culture and decreased tumor volume in xenograft models (PMID: 27469115).",
            "molecularProfile": {
                "id": 26785,
                "profileName": "BIRC2 pos FADD pos"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26248,
            "profileName": "BIRC2 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26249,
            "profileName": "BIRC2 pos TNF pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26331,
            "profileName": "BIRC2 pos BRCA1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26783,
            "profileName": "BIRC2 pos FADD over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26785,
            "profileName": "BIRC2 pos FADD pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26787,
            "profileName": "BIRC2 pos FADD dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}